{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:04:37Z","timestamp":1762146277747,"version":"build-2065373602"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004595","name":"Universiti Sains Malaysia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental and Molecular Pathology"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.yexmp.2019.104362","type":"journal-article","created":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T00:23:52Z","timestamp":1576887832000},"page":"104362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["IGFBP-2 in cervical cancer development"],"prefix":"10.1016","volume":"113","author":[{"given":"Gurjeet","family":"Kaur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shandra Devi","family":"Balasubramaniam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung Jen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexmp.2019.104362_bb0005","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/PAI.0b013e3128052936","article-title":"IGFBP2 as an immunohistochemical marker for prostatic adenocarcinoma","volume":"19","author":"Ambrosini-Spaltro","year":"2011","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.yexmp.2019.104362_bb0010","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/onc.2012.630","article-title":"IGFBP-2 nuclear translocation is mediated by a functional NLS sequence and is essential for its pro-tumorigenic actions in cancer cells","volume":"33","author":"Azar","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.yexmp.2019.104362_bb0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1309\/AJCPR11DEAYPTUSL","article-title":"Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer","volume":"141","author":"Dean","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.yexmp.2019.104362_bb0020","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.3892\/or.2014.3505","article-title":"IGF axis and other factors in HPV-related and HPV-unrelated carcinogenesis","volume":"32","author":"Durzy\u0144ska","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.yexmp.2019.104362_bb0025","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1210\/endo.142.4.8084","article-title":"In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade","volume":"142","author":"Elmlinger","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.yexmp.2019.104362_bb0030","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1210\/er.2001-0033","article-title":"Cellular actions of the insulin-like growth factor binding proteins","volume":"23","author":"Firth","year":"2002","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.yexmp.2019.104362_bb0035","first-page":"2308","article-title":"Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor","volume":"82","author":"Flyvbjerg","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.yexmp.2019.104362_bb0040","first-page":"3685","article-title":"Roles of insulin-like growth factor binding protein-2 (IGFBP-2) in glioblastoma","volume":"27","author":"Fukushima","year":"2007","journal-title":"Anticancer Res."},{"key":"10.1016\/j.yexmp.2019.104362_bb0045","doi-asserted-by":"crossref","first-page":"7113","DOI":"10.1158\/0008-5472.CAN-07-0260","article-title":"Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates","volume":"67","author":"Gius","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexmp.2019.104362_bb0050","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.4161\/cbt.5.10.3455","article-title":"Insulin-like growth factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling","volume":"5","author":"Grimberg","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.yexmp.2019.104362_bb0055","article-title":"Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival","volume":"8","author":"Guo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.yexmp.2019.104362_bb0060","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2265.1997.1100922.x","article-title":"Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia","volume":"46","author":"Ho","year":"1997","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.yexmp.2019.104362_bb0065","first-page":"8601","article-title":"Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter?","volume":"61","author":"Hoeflich","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexmp.2019.104362_bb0070","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/91.3.252","article-title":"Natural history of dysplasia of the uterine cervix","volume":"91","author":"Holowaty","year":"1999","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.yexmp.2019.104362_bb0075","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.yexmp.2019.104362_bb0080","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1002\/pmic.200500555","article-title":"Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays","volume":"6","author":"Jiang","year":"2006","journal-title":"Proteomics."},{"key":"10.1016\/j.yexmp.2019.104362_bb0085","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/sj.onc.1202172","article-title":"Signaling by integrin receptors","volume":"17","author":"Kumar","year":"1998","journal-title":"Oncogene."},{"key":"10.1016\/j.yexmp.2019.104362_bb0090","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3802\/jgo.2010.21.3.174","article-title":"Plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in women with cervical neoplasia","volume":"21","author":"Lee","year":"2010","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.yexmp.2019.104362_bb0095","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbrc.2005.08.229","article-title":"PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2","volume":"336","author":"Levitt","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.yexmp.2019.104362_bb0100","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","article-title":"PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer","volume":"275","author":"Li","year":"1997","journal-title":"Science."},{"key":"10.1016\/j.yexmp.2019.104362_bb0105","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1210\/jc.2009-2668","article-title":"Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer","volume":"95","author":"Liou","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.yexmp.2019.104362_bb0110","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/MMBR.68.2.362-372.2004","article-title":"Pathogenesis of human papillomaviruses in differentiating epithelia","volume":"68","author":"Longworth","year":"2004","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.yexmp.2019.104362_bb0115","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Lorincz","year":"2002","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.yexmp.2019.104362_bb0120","doi-asserted-by":"crossref","first-page":"11598","DOI":"10.1073\/pnas.181181198","article-title":"A phosphatidylinositol 3-kinase\/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus","volume":"98","author":"Mayo","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.yexmp.2019.104362_bb0125","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1073\/pnas.0609139104","article-title":"Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K\/Akt pathway activation in glioblastoma and prostate cancer","volume":"104","author":"Mehrian-Shai","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.yexmp.2019.104362_bb0130","first-page":"1001","article-title":"The MDM2-p53 interaction","volume":"1","author":"Moll","year":"2003","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.yexmp.2019.104362_bb0135","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1093\/nar\/26.15.3453","article-title":"The MDM2 gene amplification database","volume":"26","author":"Momand","year":"1998","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.yexmp.2019.104362_bb0140","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7555\/JBR.27.20130030","article-title":"The MDM2-p53 pathway revisited","volume":"27","author":"Nag","year":"2013","journal-title":"J. Biomed. Res."},{"key":"10.1016\/j.yexmp.2019.104362_bb0145","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.gene.2017.03.018","article-title":"Systematic identification of key genes and pathways in the development of invasive cervical cancer","volume":"618","author":"Niu","year":"2017","journal-title":"Gene."},{"key":"10.1016\/j.yexmp.2019.104362_bb0150","doi-asserted-by":"crossref","first-page":"5966","DOI":"10.1038\/sj.onc.1210397","article-title":"IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells","volume":"26","author":"Perks","year":"2007","journal-title":"Oncogene."},{"key":"10.1016\/j.yexmp.2019.104362_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2015.00025","article-title":"IGF-binding protein 2\u2013oncogene or tumor suppressor?","volume":"6","author":"Pickard","year":"2015","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.yexmp.2019.104362_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004988","article-title":"HPV16 down-regulates the insulin-like growth factor binding protein 2 to promote epithelial invasion in organotypic cultures","volume":"11","author":"Pickard","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.yexmp.2019.104362_bb0165","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrc1387","article-title":"Insulin-like growth factors and neoplasia","volume":"4","author":"Pollak","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.yexmp.2019.104362_bb0170","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1054\/bjoc.2000.1462","article-title":"Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer","volume":"83","author":"Renehan","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.yexmp.2019.104362_bb0175","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/43474","article-title":"NF-\u03baB is a target of AKT in anti-apoptotic PDGF signalling","volume":"401","author":"Romashkova","year":"1999","journal-title":"Nature."},{"key":"10.1016\/j.yexmp.2019.104362_bb0180","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ghir.2004.02.003","article-title":"What\u2019s new in the IGF-binding proteins?","volume":"14","author":"Rosenzweig","year":"2004","journal-title":"Growth Hormon. IGF Res."},{"key":"10.1016\/j.yexmp.2019.104362_bb0185","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cytogfr.2014.12.001","article-title":"IGFBP-2: the dark horse in metabolism and cancer","volume":"26","author":"Russo","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.yexmp.2019.104362_bb0190","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ygyno.2004.10.012","article-title":"High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer","volume":"96","author":"Sayer","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.yexmp.2019.104362_bb0195","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1158\/1055-9965.EPI-06-0924","article-title":"Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia","volume":"16","author":"Schaffer","year":"2007","journal-title":"Cancer Epidemiology and Prevention Biomarkers."},{"key":"10.1016\/j.yexmp.2019.104362_bb0200","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1677\/jme.0.0320859","article-title":"Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells","volume":"32","author":"Schutt","year":"2004","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.yexmp.2019.104362_bb0205","doi-asserted-by":"crossref","first-page":"258","DOI":"10.7705\/biomedica.v26i2.1415","article-title":"Serum levels of insulin-like growth factor-I and-II and insulinlike growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer","volume":"26","author":"Serrano","year":"2006","journal-title":"Biomedica."},{"key":"10.1016\/j.yexmp.2019.104362_bb0210","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ghir.2007.07.001","article-title":"Insulin-like growth factor system gene expression in cervical scrapes from women with squamous intraepithelial lesions and cervical cancer","volume":"17","author":"Serrano","year":"2007","journal-title":"Growth Hormon. IGF Res."},{"key":"10.1016\/j.yexmp.2019.104362_bb0215","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.22527","article-title":"Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update","volume":"121","author":"Smith","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexmp.2019.104362_bb0220","series-title":"Seminars in Cancer Biology","first-page":"62","article-title":"PKB\/Akt-dependent regulation of inflammation in cancer","volume":"Vol. 48","author":"Tang","year":"2018"},{"key":"10.1016\/j.yexmp.2019.104362_bb0225","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/nbt1210-1248","article-title":"Towards a knowledge-based human protein atlas","volume":"28","author":"Uhlen","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.yexmp.2019.104362_bb0230","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/bjc.2011.127","article-title":"Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or-independent mechanisms and reduces the efficacy of docetaxel","volume":"104","author":"Uzoh","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.yexmp.2019.104362_bb0235","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-kinase\u2013AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.yexmp.2019.104362_bb0240","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/modpathol.3800637","article-title":"Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types","volume":"19","author":"Wang","year":"2006","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.yexmp.2019.104362_bb0245","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ecl.2012.04.014","article-title":"The insulin-like growth factor system in cancer","volume":"41","author":"Weroha","year":"2012","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.yexmp.2019.104362_bb0250","first-page":"3356","article-title":"Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix","volume":"9","author":"Wu","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexmp.2019.104362_bb0255","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12079-015-0261-2","article-title":"IGFBP-2-taking the lead in growth, metabolism and cancer","volume":"9","author":"Yau","year":"2015","journal-title":"J. Cell. Commun. Signal."},{"key":"10.1016\/j.yexmp.2019.104362_bb0260","doi-asserted-by":"crossref","first-page":"976","DOI":"10.2353\/ajpath.2009.081004","article-title":"Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer","volume":"175","author":"Yazawa","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.yexmp.2019.104362_bb0265","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1097\/IGC.0000000000000153","article-title":"Twelve serum proteins progressively increase with disease stage in squamous cell cervical cancer patients","volume":"24","author":"Zhi","year":"2014","journal-title":"International Journal of Gynecologic Cancer."},{"key":"10.1016\/j.yexmp.2019.104362_bb0270","article-title":"Development of IGF signaling antibody arrays for the identification of hepatocellular carcinoma biomarkers","volume":"7","author":"Zhou","year":"2012","journal-title":"PLoS One"}],"container-title":["Experimental and Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448001930632X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448001930632X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:01:30Z","timestamp":1762146090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448001930632X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":54,"alternative-id":["S001448001930632X"],"URL":"https:\/\/doi.org\/10.1016\/j.yexmp.2019.104362","relation":{},"ISSN":["0014-4800"],"issn-type":[{"type":"print","value":"0014-4800"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IGFBP-2 in cervical cancer development","name":"articletitle","label":"Article Title"},{"value":"Experimental and Molecular Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexmp.2019.104362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104362"}}